# APOGEPHA Arzneimittel GmbH Company profile · Large company (from the award notice) - Legal form: GmbH - Seat: Dresden, Germany Based on the notices and sources Inteliwert covers; not a complete record. Last checked 31 October 2026. ## Identifiers Not found in the indexed notices. ## Track record in public tenders Awards in the covered notices over the last 36 months, per CPV division. | CPV division | Awards | Award value (excl. VAT) | Buyers | Repeat buyers | First award | Last award | | --- | ---: | ---: | ---: | ---: | --- | --- | | 33 Medical equipments, pharmaceuticals and personal care products | 2 | — | 1 | 1 | 31 October 2026 | 31 October 2026 | Based on the notices and sources Inteliwert covers; not a complete record. ### Awards - [Vergaben von Arzneimitteln und apothekenüblichen Produkten zum 01.01.2027 und 01.07.2027](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0) Buyer: PBMG eG · Awarded: 31 October 2026 · CPV 33600000 - [Vergaben von Arzneimitteln und apothekenüblichen Produkten zum 01.01.2027 und 01.07.2027](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0) Buyer: PBMG eG · Awarded: 31 October 2026 · CPV 33600000 ## Certifications and prequalification No certification or prequalification found in the covered sources. A certification missing here is unknown, not absent. ## Website and LinkedIn Not found in the indexed notices. ## Open tenders that might fit *Possible match based on public information* Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances. - [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Certolizumab pegol (ATC-Code nach WHO: L04AB05)](https://inteliwert.com/tender/opp_E0TZH94J4ZMJFFVYKXAT6DESR7/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei) Open · Established supplier · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 31 Dec 2026, 23:59 (UTC+01:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/6b4eb660-3682-4044-96ac-8c58769d7741), Last checked 26 Oct 2026, 15:21 (UTC+01:00) - Won a contract in CPV group 336 (2026-10-31): [Evidence](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0), checked 4 Nov 2026 - Seat in the same district as the place of performance: [Evidence](https://inteliwert.com/company/org_BCRYFQVACWJ6ZNJQ5RFRNWQFFJ), checked 4 Nov 2026 - 2 awards in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0), checked 4 Nov 2026 - [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Certolizumab pegol (ATC-Code nach WHO: L04AB05)](https://inteliwert.com/tender/opp_5AWTAP8ZWFTJBR0SP210H1JF6W/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei) Open · Established supplier · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 30 Jun 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/ece8bf22-9c28-4636-abd8-e9f76392d6ba), Last checked 26 Oct 2026, 15:21 (UTC+01:00) - Won a contract in CPV group 336 (2026-10-31): [Evidence](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0), checked 4 Nov 2026 - Seat in the same district as the place of performance: [Evidence](https://inteliwert.com/company/org_BCRYFQVACWJ6ZNJQ5RFRNWQFFJ), checked 4 Nov 2026 - 2 awards in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0), checked 4 Nov 2026 - [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab zur subkutanen Injektion (ATC-Code nach WHO: L04AB02)](https://inteliwert.com/tender/opp_BQ6YKZ3C2EDWRNVQ7X2K5E8AFX/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei) Open · Established supplier · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 30 Jun 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/4f1e68d4-7e64-4c82-8599-813990d040cc), Last checked 4 Nov 2026, 16:10 (UTC+01:00) - Won a contract in CPV group 336 (2026-10-31): [Evidence](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0), checked 5 Nov 2026 - Seat in the same district as the place of performance: [Evidence](https://inteliwert.com/company/org_BCRYFQVACWJ6ZNJQ5RFRNWQFFJ), checked 5 Nov 2026 - 2 awards in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0), checked 5 Nov 2026 - [Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tocilizumab (ATC-Code nach WHO: L04AC07)](https://inteliwert.com/tender/opp_VPEG1GR6YAXZ1HZ2AYEYY92RQC/abschluss-nicht-exkl-arzneimittel-rabattvereinb-nach-130a-abs-8-sgb-v-im-wege-ei) Open · Established supplier · Buyer: AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Deadline: 31 Jul 2028, 23:59 (UTC+02:00) · [Official notice](https://oeffentlichevergabe.de/ui/de/notices/8c8c04e5-cd46-4a1e-92c9-0ecea1756598), Last checked 4 Nov 2026, 16:10 (UTC+01:00) - Won a contract in CPV group 336 (2026-10-31): [Evidence](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0), checked 5 Nov 2026 - Seat in the same district as the place of performance: [Evidence](https://inteliwert.com/company/org_BCRYFQVACWJ6ZNJQ5RFRNWQFFJ), checked 5 Nov 2026 - 2 awards in this field in 36 months, from 1 buyer: [Evidence](https://inteliwert.com/tender/opp_30RY91PKE9HR3M00WXQWCES8R1/vergaben-von-arzneimitteln-und-apothekenueblichen-produkten-zum-01-01-2027-und-0), checked 5 Nov 2026 ## Is this your company? Send corrections, or ask us to remove the profile, to . You can also ask that the company never be tagged on LinkedIn. ## About this profile Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances. **Based on the notices and sources Inteliwert covers; not a complete record.** Last checked 31 October 2026. --- Page: https://inteliwert.com/company/org_BCRYFQVACWJ6ZNJQ5RFRNWQFFJ/apogepha-arzneimittel-gmbh Inteliwert is a product of Bandpey GmbH, an international data and AI software company in Munich, Germany, founded and led by Roozbeh Bandpey. Bandpey's products: Facthory, Emolysis, Copolly and Inteliwert. Inteliwert on LinkedIn: https://www.linkedin.com/company/intelliwert, GitHub: https://github.com/inteliwertai.